Skip to content

Malignant Hyperthermia and Kidney Transplantation

Anesthesia for Malignant Hyperthermia in the context of Kidney Transplantation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-6s332z3
Enrollment
Unknown
Registered
2024-08-28
Start date
2019-10-05
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscular Diseases

Interventions

This is a controlled, observational, cross-sectional study. A group of 10 recipient patients underwent total intravenous general anesthesia for kidney transplantation, whose respective 10 donor patien
V03.175.500

Sponsors

Escola Paulista de Medicina da Universidade Federal de São Paulo
Lead Sponsor
Escola Paulista de Medicina da Universidade Federal de São Paulo
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients scheduled for living donor kidney transplantation; living patients scheduled for total nephrectomy for donation; both sexes

Exclusion criteria

Exclusion criteria: Patients with a previous history of intraoperative awakening; family or personal history of susceptibility to malignant hyperthermia (MH); contraindications to the use of halogenated inhaled anesthetics

Design outcomes

Primary

MeasureTime frame
Expected outcome 1: Detection of halogenated inhalational anesthetics in the expired gas of a kidney transplant recipient who underwent total intravenous anesthesia. An increase in halogenated inhalation anesthetics concentration is expected in the period immediately following reperfusion of the transplanted kidney, verified using the anesthetic gas meter based on the observation of a variation of at least 0.1% in pre- and post-reperfusion measurements ;Outcome found 1: An increase in halogenated inhalation anesthetics concentration of 0.1%was observed in the period immediately following reperfusion of the transplanted kidney, verified using the anesthetic gas meter, in two patients from sevoflurane group

Secondary

MeasureTime frame
Expected outcome 2: Detection of halogenated inhalational anesthetics in the perfusion solution of the harvested kidney. But It was not possible to perform this measurement;Outcome found 2: It was not possible to perform this measurement of halogenated inhalational anesthetics in the perfusion solution of the harvested kidney

Countries

Brazil

Contacts

Public ContactMarcia Santos

Escola Paulista de Medicina da Universidade Federal de São Paulo

anestesia.dcir@unifesp.br+55-11-55764092

Outcome results

None listed

Source: REBEC (via WHO ICTRP)